You are here

Article Text

Article menu
Letters to the editor
Severe toxic neuropathy due to fibrates
  1. P CORCIA,
  2. B DE TOFFOL,
  3. C HOMMET,
  4. A AUTRET
  1. Clinique Neurologique
  2. Service de pharmacovigilance, CHU Bretonneau, 2 bis boulevard Tonnelle, 37044 Tours Cedex, France
  1. Dr P Corcia, Clinique Neurologique, CHU Bretonneau, 2 Bd Tonnellé, 37044 Tours, Cedex, France. Fax 0033 2 47 47 38 08; email corcia{at}med.univ-tours.fr
  1. A P JONVILLE-BERA
  1. Clinique Neurologique
  2. Service de pharmacovigilance, CHU Bretonneau, 2 bis boulevard Tonnelle, 37044 Tours Cedex, France
  1. Dr P Corcia, Clinique Neurologique, CHU Bretonneau, 2 Bd Tonnellé, 37044 Tours, Cedex, France. Fax 0033 2 47 47 38 08; email corcia{at}med.univ-tours.fr

https://doi.org/10.1136/jnnp.66.3.410a

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The main adverse effects of lipid lowering agents in the fibrate family involve the gut, the skin, the liver, the blood, and the muscular system. Some of these complications are more frequent when renal failure exists.1 Here we report a case of neuropathy secondary to long term treatment with fenofibrate in a patient without renal failure taking recommended doses.

    A 60 year old man was seen in September 1996 complaining of leg pain for 6 months. His relevant medical history included coronary artery disease treated for 10 years with 6 mg molsidomine/ day and 60 mg isosorbide dinitrate/ day, high blood pressure and hyperlipidaemia treated respectively with 100 mg atenolol/ day and 200 mg fenofibrate/day for the past …

    View Full Text